August 13, 2022 PR-M08-22-02
The Be The Match Registry® includes more than 266,000 fully characterized CBUs, allowing for therapy-matched unit identification.
MINNEAPOLIS, Minn. – (BUSINESS WIRE) — Be The Match BioTherapies® announced it is now providing cryopreserved Cord Blood Units as allogeneic cell therapy starting material for non-clinical, clinical, and commercial use. The Be The Match Registry®, with more than 266,000 fully-characterized cord blood units (CBU) from domestic cord blood banks, provides extensive characterization information about each CBU to allow for therapy-matched unit identification.
“The breadth of our cord blood unit registry and the depth of information we provide about each CBU aids developers as they source material for clinical trials, commercial use, or non-clinical research (RUO),” said Donna Regan, Senior Director, Customer Ready Products at NMDP/Be The Match. “Our team’s logistics and supply chain management experience ensure that temperature and time sensitive, cryopreserved CBUs safely arrive when and where they are needed.”
Since CBUs are processed and cryopreserved at multiple cord blood banks across the US, identifying the facilities with CBUs meeting specific characteristics can be challenging. Once located, developers must qualify and contract with each cord blood bank, which takes time and resources. Through a single point of access, Be The Match BioTherapies centralizes access to fully characterized CBUs through a Cord Blood Bank Alliance, effectively eliminating these challenges. The Cord Blood Bank Alliance is a cooperative association of NMDP/Be The Match and its network of member cord blood banks, formed to support the development and commercialization of emerging cell and therapies. These banks have an established history of manufacturing high-quality cord blood grafts and a demonstrated commitment to serving the needs of patients.
This service assures developers have access to cord blood units that are compliant with FDA Good Tissue and Manufacturing Practices, and a proven safety and efficacy record in human indications.
For more information, please visit the website: https://bethematchbiotherapies.com/cord-blood-units-cell-therapy/ and subscribe to the Cell Lines Blog: https://bethematchbiotherapies.com/cell-lines-blog/cord-blood-as-allogeneic-source-material/.
Bonnie Quintanilla, firstname.lastname@example.org
Phyllis Grabot, email@example.com
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of the National Marrow Donor Program®/Be The Match® and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance the development of cell and gene therapies across the globe.
Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the Be The Match Registry®, the world’s most diverse registry of more than 9 million potential blood stem cell donors in the U.S. with access to up to 39 million potential donors worldwide. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. Be The Match BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to successfully transport and deliver regulatory-compliant life-saving therapies across the globe. Through the CIBMTR, Be The Match BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.